ALGS —Two takeaways from today's Leerink webcast on ALGS-9711 (oral coronavirus protease inhibitor): 1) ALGS-097111 phase-1 won’t start until 2023 (insofar as the IND is expected to be filed in late 2022); 2) CEO Blatt talked up combination therapy to treat COVID even while insisting compound is “best in class,” which I find curious.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.